These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 31994229)

  • 21. Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.
    Syed YY
    Am J Clin Dermatol; 2017 Feb; 18(1):147-158. PubMed ID: 28138946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry.
    Kojanova M; Hugo J; Velackova B; Cetkovska P; Fialova J; Dolezal T; Tichy M; Gkalpakiotis S;
    J Dermatolog Treat; 2022 Sep; 33(6):2827-2837. PubMed ID: 35635185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab.
    Smith SD; Conrad C; Ramharter M; Gottlieb AB; Patel H; Xu W; Riedl E; Schuster C
    J Am Acad Dermatol; 2020 Jul; 83(1):261-263. PubMed ID: 32092375
    [No Abstract]   [Full Text] [Related]  

  • 24. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
    Papp KA; Gooderham M; Lynde C; Brassard D; Al-Mohammedi F; Prajapati VH; Delorme I; Albrecht L; Haydey R; Alam MS; Beecker J; Siddha S; Maguin M; Farag MS; Vieira A; Rihakova L; Langley RG
    Arch Dermatol Res; 2024 Jun; 316(7):362. PubMed ID: 38850346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis.
    Chigutsa E; Velez de Mendizabal N; Chua L; Heathman M; Friedrich S; Jackson K; Reich K
    J Clin Pharmacol; 2018 Nov; 58(11):1489-1500. PubMed ID: 29878382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment.
    Abdin R; Gharib R; Bunick CG; Issa NT
    J Drugs Dermatol; 2024 Aug; 23(8):694-696. PubMed ID: 39093648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Kimura R; Sugita K; Yamamoto O
    Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
    [No Abstract]   [Full Text] [Related]  

  • 28. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
    Leonardi C; Matheson R; Zachariae C; Cameron G; Li L; Edson-Heredia E; Braun D; Banerjee S
    N Engl J Med; 2012 Mar; 366(13):1190-9. PubMed ID: 22455413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T; Schäkel K
    J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis.
    Romiti R; Valenzuela F; Chouela EN; Xu W; Pangallo B; Moriarty SR; Gürbüz S; Riedl E
    Br J Dermatol; 2019 Jul; 181(1):202-203. PubMed ID: 30609008
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
    Zachariae C; Gordon K; Kimball AB; Lebwohl M; Blauvelt A; Leonardi C; Braun D; McKean-Matthews M; Burge R; Cameron G
    J Am Acad Dermatol; 2018 Aug; 79(2):294-301.e6. PubMed ID: 29653208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.
    Georgakopoulos JR; Phung M; Ighani A; Yeung J
    J Cutan Med Surg; 2019; 23(2):174-177. PubMed ID: 30449146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-IL-17 phase II data for psoriasis: A review.
    Brown G; Malakouti M; Wang E; Koo JY; Levin E
    J Dermatolog Treat; 2015 Feb; 26(1):32-6. PubMed ID: 24552447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab.
    Morita A; Tani Y; Matsumoto K; Yamaguchi M; Teshima R; Ohtsuki M
    J Dermatol; 2020 May; 47(5):452-457. PubMed ID: 32173900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of biologics in psoriasis.
    Kamata M; Tada Y
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-IL17 therapies for psoriasis.
    Silfvast-Kaiser A; Paek SY; Menter A
    Expert Opin Biol Ther; 2019 Jan; 19(1):45-54. PubMed ID: 30500317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data.
    Farahnik B; Beroukhim K; Nakamura M; Abrouk M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J
    J Drugs Dermatol; 2016 Mar; 15(3):311-6. PubMed ID: 26954316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.
    Haynes D; Strunck JL; Topham CA; Ortega-Loayza AG; Kent G; Cassidy PB; Hu R; Choate K; Wang Z; Liu Y; Greiling TM
    JAMA Dermatol; 2020 Jun; 156(6):668-675. PubMed ID: 32293641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.